Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Inclusion Criteria:

   - Histologically confirmed diagnosis of 1 of the following:

      - Malignant extracranial solid tumor

         - Recurrent or refractory disease

         - Known bone marrow metastases* allowed

      - Imatinib mesylate-resistant Philadelphia chromosome-positive (Ph+) acute
      lymphoblastic leukemia (ALL), defined as M3 bone marrow in a patient who
      previously received imatinib mesylate-containing treatment regimen

      - Imatinib mesylate-resistant Ph+ chronic myelogenous leukemia (CML), as defined by
      any of the following:

         - Increasing WBC or platelet count while on imatinib mesylate therapy

         - Lack of any cytogenetic response after an adequate duration of imatinib
         mesylate therapy, as defined by 1 of the following:

            - Failed to achieve a complete hematologic response after completion of 3
            months of imatinib mesylate treatment

            - Failed to achieve a partial or complete cytogenetic response (i.e., ≤
            35% Ph+ cells) after 6 months of imatinib mesylate treatment

         - Appearance of accelerated or blastic feature while on imatinib mesylate
         therapy

         - Reappearance of Ph+ clones after an initial complete cytogenetic response to
         imatinib mesylate

         - More than 30% increase in Ph+ cells in peripheral blood or bone marrow
         cytogenetics while on imatinib mesylate therapy

         - Imatinib mesylate intolerance, as defined by development of adverse effects
         requiring discontinuation of imatinib mesylate therapy

   - Measurable disease (for patients with CML or ALL)

      - Determined by hematologic, cytogenetic, and molecular studies for CML

      - Determined by bone marrow blast percentage for ALL

   - Measurable or evaluable disease (for patients with solid tumors)

   - No known curative therapy or survival-prolonging therapy with an acceptable quality of
   life

   - No CNS solid tumors

      - CNS-positive leukemia allowed

   - Karnofsky performance status (PS) ≥ 50% (for patients > 10 years of age)

   - Lansky PS ≥ 50% (for patients ≤ 10 years of age)

   - No evidence of graft-vs-host disease

   - Solid tumors:

      - Absolute neutrophil count ≥ 1,000/mm^3 (750/mm^3 if bone marrow infiltration)

      - Platelet count ≥ 100,000/mm^3 (transfusion independent) (50,000/mm^3 if bone
      marrow infiltration)

      - Hemoglobin ≥ 8.0 g/dL (red blood cell [RBC] transfusions allowed)

   - ALL/CML:

      - Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed)

      - Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)

   - Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR
   creatinine based on age, as follows:

      - No greater than 0.6 mg/dL (1-23 months of age)

      - No greater than 0.8 mg/dL (2- 5 years of age)

      - No greater than 1.0 mg/dL (6-9 years of age)

      - No greater than 1.2 mg/dL (10-12 years of age)

      - No greater than 1.4 mg/dL (13 years of age and over [female])

      - No greater than 1.5 mg/dL (13-15 years of age [male])

      - No greater than 1.7 mg/dL (16 years of age and over [male])

   - Bilirubin ≤ 1.5 times upper limit of normal (ULN)

   - ALT ≤ 110 U/L

   - Albumin ≥ 2 g/dL

   - Normal 12-lead EKG with corrected QTc < 450 msec AND meets 1 of the following
   criteria:

      - Shortening fraction normal

      - Ejection fraction normal

   - No evidence of dyspnea at rest

   - No exercise intolerance

   - Pulse oximetry > 94% if there is a clinical indication for determination

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - No uncontrolled infection

   - No swallowing dysfunction that would prevent taking an oral or liquid medication

   - See Disease Characteristics

   - Recovered from prior chemotherapy, immunotherapy, or radiotherapy

   - No myelosuppressive chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)

   - At least 7 days since prior growth factors

   - At least 14 days since prior pegfilgrastim

   - At least 7 days since prior biologic agents

   - At least 2 weeks since prior local small-port palliative radiotherapy

   - At least 3 months since prior total-body irradiation, craniospinal radiation, or
   radiation to ≥ 50% of the pelvis

   - At least 6 weeks since other prior substantial bone marrow radiation

   - At least 3 months since prior stem cell transplantation

   - Hydroxyurea cytoreduction for Ph+ leukemia allowed provided it is discontinued 24
   hours before first dose of dasatinib

   - Prior intrathecal (IT) therapy allowed (for patients with CNS-positive leukemia)

   - Concurrent IT therapy comprising hydrocortisone, cytarabine, methotrexate, or
   cytarabine (liposomal) allowed (for patients with CNS-positive leukemia)

   - No other concurrent investigational drugs

   - No other concurrent anticancer agents, including chemotherapy, radiotherapy,
   immunotherapy, or biologic therapy

   - No concurrent enzyme-inducing anticonvulsants, including any of the following:

      - Phenytoin

      - Phenobarbital

      - Carbamazepine

      - Felbamate

      - Primdone

      - Oxcarbazepine

   - No concurrent antithrombotic or antiplatelet agents, including any of the following:

      - Warfarin

      - Heparin

      - Low-molecular weight heparin

      - Aspirin

      - Ibuprofen

      - Other nonsteroidal anti-inflammatory drugs

   - No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, and
   voriconazole

   - No concurrent highly active antiretroviral treatment for HIV-positive patients